Status: Recruiting
Palbociclib and Pembrolizumab in Sarcoma
This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib in patients with soft tissue sarcomas for which PD-1 inhibitors are approved (includes undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, or alveolar soft part sarcoma).
Participants needed: 8
Trial details
Phase: Phase 1Age: 12+Biological sex: AllType: InterventionalSponsor: John RiethUpdated: May 22, 2026Locations: 1
Eligibility criteria
Male or female patients aged > or = 12 years old [+4]
Neutrophil count < 1000/mm3 [+18]